We are an innovative biotechnology company focused on the development of new targeted therapies based on nanotechnology. We search for and develop new drug synergies in the treatment of diseases with unmet medical needs.

We are also rapidly advancing new products based on siRNA technology, which enables us to target entirely new therapeutic targets objectives. Our primary focus lies in oncology as the main goal of our activities.

We concentrate on developing new products starting from basic research, preclinical, and clinical trials. Our goal is to introduce new nanotherapies with a global reach. Our mission is to increase patient access to innovative clinical therapies.

Team BS Biotechna

The founders of BS Biotechna bring years of experience gained at global pharmaceutical companies in key positions responsible for the development of therapies at preclinical phase, I-III clinical trials, and post-marketing studies. Seven of these projects are already registered therapies, generating a revenue of over 10 billion USD annually. We have the expertise and competence to independently design and conduct preclinical and clinical research. The scientists forming BS Biotechna team are top-tier professionals in the field of nanochemistry, biology, and medicine. They are passionate individuals with a significant track record and are renowned worldwide in their field.


Searching for new synergies and new indications for known compounds to enhance efficiency and accelerate the development path of new drugs, reducing associated risks and costs.

We have more than 20 confirmed high-efficacy synergies in over 10 types of cancer, including breast, lung, and brain tumors, for which we have developed a nanoparticle platform.

Developing innovative RNA and DNA-based products for new targets in cancer treatment.

Our delivery system ensures the stability of nucleic acids and effective delivery.

Developing our proprietary nanoparticle platform for the delivery of nucleic acids and small molecules

Advancing nanotechnology is a particular area of interest. Leveraging our knowledge and experience, we are developing our own structures with various physicochemical properties, aiming to deliver multiple synergistic drugs with the goal of overcoming adaptive resistance. This serves as a foundation for enhancing effectiveness and reducing toxicity beyond the treatment target.We possess the capability to create a nanoparticle platform with a wide range of flexibility, allowing us to diversify our portfolio focused on oncology and its unmet medical needs. This includes cancers such as small cell lung cancer (SCLC), non-small cell lung cancer (NSCLC), sarcomas, urothelial carcinoma, pancreatic adenocarcinoma, ovarian cancer, and more.

Scroll to Top